Loading
A phase 1/2 trial of LEE011 in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer is a phase 1/2 interventional study registered as NCT01872260 by Novartis Pharmaceuticals, with 255 participants enrolled, started 2013-10-22 and due to reach its primary completion in 2027-02-26. Interventions recorded: LEE011, Letrozole and BYL719.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/